Taihu Bay CEIBS Forum on Value Investment and Creation in the Healthcare Industry Concludes Successfully in Wuxi
December 6, 2020,Taihu Bay China-Europe · Lun Dao EventSuccessfully held in Wuxi. The event, themed “"Value Investment and Creation in the Healthcare Industry Under New Circumstances"Centered on the themes of “Change” and “Transformation,” the event features discussions from investment perspectives, including primary and secondary markets. It is hosted by the Wuxi Science and Technology Bureau, the Administrative Committee of Wuxi High-Tech Industrial Development Zone, and the Investment Special Committee of the CEIBS Alumni Healthcare Industry Association. The organizers include Wuxi International Life Science Innovation Park (I·Campus), the Wuxi Center of the CEIBS Alumni Healthcare Industry Association, and the Wuxi Biopharmaceutical Industry Association. VCBeat serves as the executive organizer, with support from the Wuxi Enterprise Innovation Service Association.
Gao Yaguang, Deputy Mayor of Wuxi Municipal People’s Government; Cui Rongguo, Deputy Secretary of the Party Working Committee of Wuxi National Hi-Tech Industrial Development Zone, Director of its Administrative Committee, Deputy Secretary of the CPC Xinwu District Committee, and Acting District Mayor; Wang Lei, President of the CEIBS Alumni Healthcare Industry Association; and Fan Yin, Chairman of the Investment Professional Committee of the CEIBS Alumni Healthcare Industry Association attended the event and delivered speeches. Meanwhile, Sun Haidong, Director of the Wuxi Science and Technology Bureau, spoke as the representative of CEIBS alumni in Wuxi.
Gao Yaguang, Vice Mayor of Wuxi Municipal People's Government
Gao Yaguang stated that Wuxi’s biomedical industry has made significant new progress this year. Wuxi will officially build the Taihu Bay Science and Technology Innovation Belt, prioritizing the biomedical industry as the flagship project in its core strategy of innovation-driven development. The city aims to cultivate the biomedical sector into a world-class industrial cluster, further enhancing awareness and focus across the entire municipality on accelerating the development of the biomedical industry.
Cui Rongguo, Deputy Secretary of the Party Working Committee and Director of the Administrative Committee of Wuxi High-Tech Zone; Deputy Secretary of the CPC Xinwu District Committee and Acting District Mayor
Cui Rongguo stated that Wuxi will strengthen industry chain-oriented investment promotion, leverage existing businesses to attract new ones, and accelerate the aggregation of domestic and international resources. The Wuxi High-Tech Zone will fully leverage its advantages and continue to support the development of the biopharmaceutical industry, providing a favorable policy environment and optimal safeguards for corporate growth, technological R&D, and project advancement.
Wang Lei, President of the CEIBS Alumni Association for Healthcare Industry
Wang Lei also serves asPresident of the CEIBS Alumni Healthcare Industry Association, and Global Executive Vice President of AstraZeneca as well as President for International Business and China,It expressed the hope that Wuxi would continuously leverage its advantages in government-enterprise collaboration and its international character, achieve closer global cooperation, attract more domestic and overseas enterprises to settle in, and work together with innovative startups, incubators, and industry associations to stimulate deep integration of the industrial chain.
Fan Yin, President of the Investment Professional Committee of the CEIBS Alumni Healthcare Industry Association and President of Jinpu Health Services
Fan Yin stated that the Investment Committee of the CEIBS Alumni Healthcare Industry Association would uphold the principle of leveraging professional expertise to empower the sector, by integrating relevant resources and facilitating efficient linkages, so as to achieve industry collaboration between domestic and overseas markets, optimize the allocation of medical resources, and provide specialized empowerment.
Sun Haidong, Director of the Wuxi Municipal Science and Technology Bureau
Sun Haidong stated that Wuxi will focus on two systems—the industrial ecosystem and the innovation ecosystem—and strive for excellence in five key areas: internationally first-class innovative drugs and health foods, domestically first-class high-end precision devices, precision medicine, and digital healthcare. The goal is to cultivate a robust biopharmaceutical industrial ecosystem. Future cooperation will become more closely knit, with Wuxi providing more opportunities for a greater number of enterprises and creating a more favorable environment and conditions for their development.
Establishment of the Wuxi Biopharmaceutical Industry Association and Signing Ceremony with Friendly Industry Associations
It is reported that the event also featured the unveiling ceremony for the establishment of the Wuxi Biopharmaceutical Industry Association. Two friendly industry associations, the Shanghai Biopharmaceutical Industry Association and the Hangzhou Pharmaceutical Industry Association, signed cooperation agreements with it on site.Yu Jianghua, President of the Wuxi Biopharmaceutical Industry Associationstated that the association would take “enhancing industry services, promoting self-discipline, representing the industry, and facilitating industry coordination” as its core missions, fully leverage its role as a bridge and link between enterprises and the market as well as between enterprises and the government, integrate various resources for the industry, foster a favorable ecosystem, and unite efforts to jointly achieve high-quality industry development.
That afternoon,“Jinfeng Club” China Healthcare Industry Investment Elite ClubandExpert Advisory Committee of the CEIBS Alumni Healthcare Industry AssociationBoth were established, and the member list was announced at the event. The “Jinfeng Club,” a China Healthcare Industry Investment Elite Club, is a newly established private club built upon the foundation of the Investment Special Committee of the CEIBS Healthcare Association. It aims to bring together visionary and mission-driven investors in the broader health industry to explore technological and business model innovations in the healthcare sector, thereby discovering and creating value. The Expert Advisory Committee of the CEIBS Alumni Healthcare Industry Association will also invite influential industry leaders and innovative entrepreneurs to join the association’s platform, providing opinions and guidance for the association’s long-term and healthy development, as well as resources for its activities. It is believed that professional organizations such as the “Jinfeng Club” and the Expert Advisory Committee will help the CEIBS Alumni Health Industry Association better buildAn interactive platform across and within industries, driving healthcare policy and systemic reform in China.
At the conference, renowned experts including Professor Li Mingjun of CEIBS, Academician Ma Dawei of the Chinese Academy of Sciences, and Jin Chunlin, Director of the Shanghai Center for Health Development and Research, engaged in in-depth discussions with alumni from the investment community representing CICC Capital, Hankang Capital, and Guolian Securities. Meanwhile, representatives from leading enterprises such as WuXi AppTec, LinkDoc, and Vazyme delivered keynote speeches, jointly exploring value investment and value creation in the healthcare industry under the new landscape.
Li Mingjun, Professor at CEIBS
President Li Mingjun shared his reflections on the current international situation, stating that as Chinese enterprises pursue future development, entrepreneurs must not only focus on their own operational management but also pay close attention to interstate relations and shifts in the global landscape.
Ma Dawei, Academician of the Chinese Academy of Sciences
Academician Ma Dawei of the Chinese Academy of Sciences shared insights on new models for drug research and development, stating that source innovation combined with corporate operation is the key to successfully translating innovative achievements. Meanwhile, Academician Ma urged the community to be sufficiently inclusive and patient toward innovation, as clinical research is a lengthy process.
Jin Chunlin, Director of the Shanghai Health and Health Development Research Center
Jin Chunlin, Director of the Shanghai Health and Health Development Research Center, elaborated on four key aspects: an overview of healthcare reform, DRG-based health insurance payment reform, volume-based procurement of pharmaceuticals and medical consumables, and the “Four Subsidies” policy for health insurance. Director Jin argued that healthcare reform should use payment system reform as its entry point, be guided by therapeutic efficacy and health outcomes, leverage advancements in medical technology as a vehicle, and identify optimal treatment pathways.
Yang Qing, Co-CEO of WuXi AppTec, and Shan Junbao, Co-President of CICC Capital, both shared their insights at the event from the perspectives of corporate development and future investment.
From left to right: Ge Yongbin, Jin Chunlin, Zhang Tianze, Yuan Quanhong, Ma Qunxing, Cao Lin
On the day of the event, Jin Chunlin, Director of the Shanghai Health and Development Research Center; Zhang Tianze, Founder of LinkDoc Technology; Yuan Quanhong, Founding Partner of Hankang Capital; Ma Qunxing, Vice President of Guolian Securities; Cao Lin, Founder of Vazyme; and Ge Yongbin, Partner at Zhong Lun Law Firm, attended the afternoon roundtable discussion. Under the theme “The Great Tides of the Era and the Small Waves of Individuals,” they discussed the future of the healthcare industry. Key challenges facing all practitioners include innovation and transformation at the technological foundation, the future payment system for the biopharmaceutical industry, positive incentive mechanisms for all stakeholders, entrepreneurs’ self-breakthroughs, and continuous improvement in management.
From left to right: Luo Nianci, Yu Jiangtao, Wu Aimin, Li Qingyang
In the afternoon, Yu Jiangtao, Healthcare Investment Advisor at Gaorong Capital; Wu Aimin, President of Sinopharm Capital Co., Ltd.; Li Qingyang, Executive Director of Shougang Fund and Head of Equity FOFs; and Luo Nianci, Executive Vice President of the CEIBS Alumni Healthcare Industry Association, engaged in detailed discussions on the primary and secondary markets of healthcare investment. They emphasized that fund-of-funds (FOFs) should transition from passive to active investment strategies. In the primary market, tax policies and a shortage of professional institutions are the main factors affecting healthcare investments. For the secondary market, beyond the selection of founding teams, initial corporate governance design is crucial. True value investment—whether based on innovation, business models, or internationalization—will ultimately be reflected in the capital markets as long as genuine value exists.
Seizing the opportunity presented by the conference, Wuxi will accelerate the development of its biopharmaceutical industry, expand its scale, and fully promote high-end, green, intelligent, and international development. The city aims to actively build a biopharmaceutical hub with regional characteristics and independent innovation capabilities, striving to achieve an industry scale of RMB 200 billion and gather approximately 1,500 biopharmaceutical enterprises by the end of 2022.